Terence W. Friedlander

Also affiliated with UCSF Helen Diller Family Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 21 papers. Top paper: “Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer”.

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

Cell(2020)10.1016/j.cell.2020.05.017

N/A

5.5DataRank · unranked

749 citations

Serena S. Kwek, Siddharth S. Raju, Tony Li, Elizabeth McCarthy, Eric D. Chow +15 more

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Journal of Clinical Oncology(2023)10.1200/jco.22.02887

N/A

4.4DataRank · unranked

181 citations

Matthew I. Milowsky, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar +20 more

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-002254

N/A

1.6DataRank · unranked

72 citations

Li Zhang, Sumit K. Subudhi, Brandon Chen, Jaqueline Marquez, Eric V Liu +12 more

Cell-free DNA as a biomarker for prostate cancer: elevated concentration and decreased fragment size

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.07.26.215020

N/A

0DataRank · unranked

0 citations

Clinton L. Cario, Lancelote Leong, Karen López, César Márquez, Carissa Chu +14 more

Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4175

N/A

0DataRank · unranked

156 citations

Martin Sjöström, Emily A. Egusa, Ewan A. Gibb, Michelle L. Badura, Jun Zhu +11 more

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Cancer(2021)10.1002/cncr.34057

N/A

0DataRank · unranked

86 citations

Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam +31 more

Cell-free DNA concentration and fragment size as a biomarker for prostate cancer

Scientific Reports(2021)10.1038/s41598-021-84507-z

N/A

0DataRank · unranked

79 citations

Clinton L. Cario, Lancelote Leong, Karen López, César Márquez, Carissa Chu +14 more

Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing

JCO Precision Oncology(2021)10.1200/po.20.00428

N/A

0DataRank · unranked

11 citations

Clinton L. Cario, Lancelote Leong, Karen López, César Márquez, Patricia Li +14 more

Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5053

N/A

0DataRank · unranked

32 citations

Srey Luch Sam, Vadim S. Koshkin, Eric J. Small, Felix Y. Feng, Ivan de Kouchkovsky +12 more

Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.442

N/A

0DataRank · unranked

8 citations

Divya Natesan, Li Zhang, David Y. Oh, Sima P. Porten, Maxwell V. Meng +6 more

Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e16510

N/A

0DataRank · unranked

5 citations

Li Zhang, David Y. Oh, Sima P. Porten, Maxwell V. Meng, Raj S. Pruthi +15 more

The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5045

N/A

0DataRank · unranked

4 citations

Meenal Sinha, Sumit K. Subudhi, Brandon Chen, Jaqueline Marquez, Eric Liu +12 more

TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells

European Urology Oncology(2022)10.1016/j.euo.2021.11.005

N/A

0DataRank · unranked

87 citations

Kai Trepka, Martin Sjöström, Emily A. Egusa, Carissa Chu, Jun Zhu +14 more

Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention

Urologic Oncology Seminars and Original Investigations(2022)10.1016/j.urolonc.2022.11.016

N/A

0DataRank · unranked

19 citations

Yea‐Hung Chen, Erin L. Van Blarigan, June M. Chan, Charles J. Ryan, Li Zhang +16 more

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4505

N/A

0DataRank · unranked

21 citations

Jonathan E. Rosenberg, Rana R. McKay, Thomas W. Flaig, Daniel P. Petrylak, Christopher Hoimes +14 more

Data from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

(2023)10.1158/1078-0432.c.6530730

N/A

0DataRank · unranked

0 citations

Martin Sjöström, Emily A. Egusa, Ewan A. Gibb, Michelle L. Badura, Jun Zhu +11 more

Data from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

(2023)10.1158/1078-0432.c.6530730.v1

N/A

0DataRank · unranked

0 citations

Martin Sjöström, Emily A. Egusa, Ewan A. Gibb, Michelle L. Badura, Jun Zhu +11 more

Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer

Nature Communications(2025)10.1038/s41467-025-62710-0

N/A

0DataRank · unranked

8 citations

Henry M. Delavan, Elizabeth Yip, Corynn Kasap, Jun Zhu, Roshan Lodha +21 more

Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3693

N/A

0DataRank · unranked

9 citations

Karen A. Autio, Christopher R. Cabanski, Kristopher Wentzel, Julie N. Graff, Terence W. Friedlander +19 more

A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer

BMC Cancer(2020)10.1186/s12885-020-07318-x

N/A

0DataRank · unranked

20 citations

Emmalyn Chen, Lancelote Leong, Nima C. Emami, Karen López, Imelda Tenggara +7 more

A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.04.30.069658

N/A

0DataRank · unranked

2 citations

Emmalyn Chen, Lancelote Leong, Nima C. Emami, Karen López, Imelda Tenggara +7 more